Name: UCL-Cytiva Centre of Excellence Annual Seminar- Hybrid event
Start: 2025-01-20T18:00:00+00:00
End: 2025-01-20T20:00:00+00:00
Location: Sir Ambrose Fleming Lecture Theatre

UCL-Cytiva Centre of Excellence Annual Seminar- Hybrid event

Shaping future therapies with biology and manufacturing (In-person and online event)
About this Event

Shaping future therapies with biology and manufacturing (In-person and online event)

Join Daria Donati, the Chief Scientific Officer of Genomic Medicine (Cytiva), at our UCL-Cytiva Centre of Excellence Annual Seminar. Daria brings over 20 years of leadership in biopharmaceutical innovation. Drawing on extensive expertise in R&D, strategic growth, and advancing genomic solutions, this seminar will delve into how biology and manufacturing are shaping the future of therapies. Discover cutting-edge strategies driving sustainable, scalable, and transformative healthcare solutions for global impact.

Speaker: Daria Donati, Chief Scientific Officer of Genomic Medicine at Cytiva. On a mission to make a difference. Daria lead the strategic direction and execution of the company's portfolio of genomic solutions, products, and services. With over 20 years of experience in biopharmaceuticals, She have a strong background in business development, R&D, marketing, and product management, as well as a PhD in Experimental Medicine from Karolinska Institute.

Daria’s many achievements include title of European businesswoman of the year in the category Life Sciences, and her pivotal role in the development of Cytiva’s KUBio solution, the world’s first modular biomanufacturing facility..

Chaired by: Dan Bracewell, Professor of Bioprocess Analysis at the UCL Department of Biochemical Engineering

The UCL- Cytiva Centre of Excellence (CoE) is a strategic industrial research initiative setup in 2018 to foster innovation, facilitate knowledge transfer, and address critical bioprocessing industrial challenges. With support from EPSRC & MRC Prosperity Partnership fund the Centre will now continue until 2029 with a focus on "Smart Biomanufacturing for Genomic Medicines," to address the challenges of manufacturing revolutionary genomic medicines. The partnership will improve patient access to these transformative therapies and establish manufacturing innovation in a high-growth sector that will result in societal and economic impact.